SOUTH EASTON, Mass., May 21 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) ("PBI") today announced that scientists from the New York University (NYU) School of Medicine, the Brooklyn Hospital Center, and the Harvard School of Public Health made presentations highlighting the advantages of the Company's patented pressure cycling technology (PCT) at three different scientific meetings earlier this week. There were three oral presentations and four poster presentations, all relating to research studies focused on cancer, stroke, obesity, biomarker discovery, and in-vitro fertilization.
BIOMARKER WORLD CONGRESS 2008 (Philadelphia, PA). Dr. Paul Pevsner (NYU School of Medicine) gave an oral presentation on Monday, May 19th on colon cancer. PCT was used by Dr. Pevsner and colleagues to extract proteins from colon tissue samples prior to analysis. Dr. Pevsner reported that new and additional proteins were extracted with PCT when compared to conventional extraction methods. Dr. Pevsner also reported that he and his colleagues were able to reduce the time required for preparing these proteins with trypsin for further analysis from 12 hours to under 45 minutes by using PCT, which he stated was a significant advantage over current techniques. Dr. Pevsner concluded that a change in the current paradigm of tumor diagnosis and staging may be needed, a paradigm in which PCT may play a pivotal role given the power of the technique to efficiently extract proteins from tissue samples and to subsequently quickly prepare them for downstream analysis.
GETTING OPTIMIZED TOOLS FOR DIAGNOSTICS (GOT Summit 2008 - Boston, MA). Dr. Alexander Ivanov (Harvard School of Public Health) gave an oral presentation on Tuesday, May 20th on the use of PCT and PCT-dependent reagents (ProteoSolve-LRS Kit) for the efficient recovery of proteins from lipid-rich adipose (fat) tissue. Adipose tissue plays a key role in several biomedical processes that are linked to obesity, insulin resistance, inflammation, and other physiological complications. Dr. Ivanov indicated that efficient and good quality analysis of adipose tissue is highly valuable in studies of these diseases. Adipose tissue is comprised of up to 80-90% lipid, which makes conventional detergent-based protein extraction methods inefficient and difficult. Dr. Ivanov found that the combination of PCT and ProteoSolve-LRS resulted in a much faster, less expensive, and higher quality extraction process, as compared to current methods.
ACS MID-ATLANTIC REGIONAL MEETING (MARM 2008 - New York, NY). Dr. Pevsner gave an oral presentation on Tuesday May 20th. In addition, he and his colleagues from the NYU School of Medicine and the Brooklyn Hospital Center also gave four poster presentations at this meeting. Dr. Pevsner's talk centered on the importance of sample preparation, and how the quality of sample preparation directly affects the quality of downstream results. Dr. Pevsner shared data illustrating the efficiency and quality of PCT results as compared to conventional methods in use today, and concluded that sample preparation using PCT resulted in a better quality extraction of proteins from tissue samples. On the same day, Dr. Pevsner and his colleagues delivered four poster presentations, which described the use of PCT in the extraction of proteins from breast and colon cancer tissue samples, as well as from the nutrient media used with in-vitro fertilization study procedures. The poster presentations reported that PCT increased protein yield and helped to identify proteins not previously seen in such samples. These presentations concluded that such enhanced extraction of proteins by PCT may result in new therapeutic strategies, diagnostic paradigms, and enhanced analysis of samples.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and higher) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of enzymes, immunodiagnostics, and protein purification.
Forward Looking Statements
Statements contained in this press release regarding the Company's
intentions, hopes, beliefs, expectations, or predictions of the future are
"forward-looking'' statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements include the reported
effectiveness of PCT to extract new proteins; the speed of sample
preparation using PCT compared with current sample preparation methods; the
importance of ProteoSolve-LRS and PCT in the reported identification of new
proteins; the speed, cost, and quality advantages of ProteoSolve-LRS and
PCT over other sample preparation methods; and the possibility that
extraction of proteins by ProteoSolve-LRS and PCT may result in new
therapeutic strategies, diagnostic paradigms, and enhanced analysis of
samples. These statements are based upon the Company's current
expectations, forecasts, and assumptions that are subject to risks,
uncertainties, and other factors that could cause actual outcomes and
results to differ materially from those indicated by these forward-looking
statements. These risks, uncertainties, and other factors include, but are
not limited to: unforeseen technological difficulties that the Company may
encounter in the development of the PCT technology and the PCT Sample
Preparation System; the possibility that due to the nature of the research
being performed, other laboratories may not find the use of ProteoSolve-LRS
and PCT to be as advantageous as reported by Dr. Ivanov and by Dr. Pevsner
and his colleagues; due to scientific and medical challenges, the
possibility that the data generated by Dr. Ivanov, and by Dr. Pevsner and
his colleagues, or that may be generated by other researchers in the
future, may not be beneficial in the development of new therapeutics and
diagnostics for breast and colon cancer, IVF, stroke, or other procedures
and diseases; that due to competitive products, services, and technological
advances, PCT may not be the preferred method of sample preparation by
other scientists and laboratories; and the other risks and uncertainties
discussed under the heading "Risk Factors" in the Company's Annual Report
on Form 10-K for the year ended December 31, 2007, and other reports filed
by the Company from time to time with the SEC. The Company undertakes no
obligation to update any of the information included in this release,
except as otherwise required by law.
Visit us at our website http://www.pressurebiosciences.com
Richard T. Schumacher, President & CEO Pressure BioSciences, Inc.
Edward H. Myles, Senior Vice President (508) 230-1828 (T)
of Finance & CFO
|SOURCE Pressure BioSciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved